Oscar Health (NYSE:OSCR) Director Mario Schlosser Sells 34,120 Shares of Stock

Oscar Health, Inc. (NYSE:OSCR) Director Mario Schlosser sold 34,120 shares of the firm’s stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $21.94, for a total transaction of $748,592.80. Following the sale, the director directly owned 480,866 shares of the company’s stock, valued at approximately $10,550,200.04. The trade was a 6.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Oscar Health Stock Up 14.8%

Shares of NYSE OSCR opened at $23.54 on Friday. Oscar Health, Inc. has a 1 year low of $10.69 and a 1 year high of $25.58. The firm has a market cap of $7.10 billion, a price-to-earnings ratio of -39.90, a PEG ratio of 1.43 and a beta of 2.37. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.11 and a current ratio of 1.11. The stock’s 50-day simple moving average is $18.15 and its 200-day simple moving average is $16.00.

Oscar Health (NYSE:OSCR) last issued its earnings results on Wednesday, May 6th. The company reported $2.07 EPS for the quarter, topping the consensus estimate of $1.11 by $0.96. The company had revenue of $4.65 billion during the quarter, compared to analyst estimates of $4.90 billion. Oscar Health had a negative return on equity of 3.26% and a negative net margin of 0.30%.The business’s revenue was up 52.6% on a year-over-year basis. During the same quarter last year, the firm earned $0.92 EPS. As a group, equities analysts anticipate that Oscar Health, Inc. will post 0.47 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in shares of Oscar Health by 2.7% in the fourth quarter. Vanguard Group Inc. now owns 20,701,250 shares of the company’s stock valued at $297,477,000 after acquiring an additional 540,851 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its holdings in shares of Oscar Health by 11.0% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 9,217,816 shares of the company’s stock valued at $132,461,000 after acquiring an additional 910,320 shares in the last quarter. Morgan Stanley boosted its holdings in shares of Oscar Health by 42.8% in the fourth quarter. Morgan Stanley now owns 6,814,046 shares of the company’s stock valued at $97,918,000 after acquiring an additional 2,043,758 shares in the last quarter. Thrive Capital Management LLC boosted its holdings in shares of Oscar Health by 33.4% in the fourth quarter. Thrive Capital Management LLC now owns 6,343,617 shares of the company’s stock valued at $85,258,000 after acquiring an additional 1,588,395 shares in the last quarter. Finally, BIT Capital GmbH boosted its holdings in shares of Oscar Health by 545.0% in the fourth quarter. BIT Capital GmbH now owns 6,186,267 shares of the company’s stock valued at $88,897,000 after acquiring an additional 5,227,152 shares in the last quarter. 75.70% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

OSCR has been the topic of several analyst reports. Barclays raised their price target on shares of Oscar Health from $21.00 to $30.00 and gave the company an “equal weight” rating in a research note on Tuesday, May 26th. Weiss Ratings restated a “sell (d)” rating on shares of Oscar Health in a research note on Tuesday, April 21st. Wolfe Research initiated coverage on shares of Oscar Health in a research note on Tuesday, May 5th. They issued a “peer perform” rating on the stock. Wells Fargo & Company set a $20.00 price target on shares of Oscar Health and gave the company an “equal weight” rating in a research note on Thursday. Finally, Raymond James Financial upgraded shares of Oscar Health from a “market perform” rating to an “outperform” rating and set a $18.00 price target on the stock in a research report on Thursday, February 12th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $20.22.

Oscar Health News Summary

Here are the key news stories impacting Oscar Health this week:

• Positive Sentiment: Wells Fargo upgraded Oscar Health from “strong sell” to “hold,” which can improve investor confidence and suggests the stock may have become less risky after its recent run-up. Zacks.com
• Positive Sentiment: Recent management commentary/news around a co-founder moving into an advisory leadership role appears to indicate an internal transition rather than a disruptive change, which the market may be viewing as neutral-to-positive. Oscar Health Co-Founder Shifts to Advisory Leadership Role
• Neutral Sentiment: Several insiders, including CFO Richard Scott Blackley, insider Janet Liang, Adam Mcananey, director Mario Schlosser, and CAO Victoria Baltrus, sold shares under pre-arranged 10b5-1 plans tied to tax withholding on equity awards. Because these are planned transactions, they are less concerning than discretionary selling, but they can still weigh on sentiment.

About Oscar Health

Oscar Health, trading on the New York Stock Exchange under the ticker OSCR, is a technology-driven health insurance company headquartered in New York, New York. Founded in 2012 by Mario Schlosser, Joshua Kushner and Kevin Nazemi, the company was built with the goal of simplifying healthcare coverage and enhancing member experience. Oscar leverages a proprietary digital platform to streamline plan enrollment, claims administration and member support, distinguishing itself in the individual, family and small group insurance markets.

The company’s primary products include on-exchange individual and family medical plans under the Affordable Care Act, off-exchange plans, as well as Medicare Advantage offerings.